1. Prognostic value of the expression of estrogen receptor β in patients with non-small cell lung cancer: a meta-analysis
- Author
-
Xiaoxia Wang, Yong Song, Ze-Jun Zhou, Ying-ying Miu, Qian Li, Yafang Liu, Jia-jia Jin, Qingqing Zhu, Lihong Ma, Tangfeng Lv, and Ping Zhan
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Evidence-Based Medicine ,business.industry ,medicine.drug_class ,Hazard ratio ,Estrogen receptor ,medicine.disease ,Confidence interval ,respiratory tract diseases ,Pathogenesis ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Estrogen ,030220 oncology & carcinogenesis ,Internal medicine ,Meta-analysis ,medicine ,Non small cell ,business ,Lung cancer - Abstract
Background: Lung cancer remains the leading cause of cancer-related deaths in men and the second leading cause in women worldwide. It is becoming increasingly clear that estrogen and estrogen receptors are involved in the pathogenesis and development of lung cancer. However, observational studies on the prognostic role of estrogen receptor β (ERβ) in non-small cell lung cancer (NSCLC) are controversial. Methods: To clarify the impact of ERβ in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios (HR) and their corresponding 95% confidence intervals (CIs) were calculated in terms of overall survival. Results: A total of eleven studies with 3,300 patients were evaluable for this meta-analysis. Our results suggested that ERβ overexpression had no relationship on survival of patients with NSCLC, the HR (95% CI) was 1.000 (0.954–1.047) overall. Moreover, there was no heterogeneity between the studies. Conclusions: ERβ overexpression indicates no relationship of prognosis for patients with NSCLC.
- Published
- 2016